Kallyope Revenue and Competitors

Claim your profile

Location

#343

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Kallyope's estimated annual revenue is currently $17.1M per year.(i)
  • Kallyope received $21.0M in venture funding in December 2018.
  • Kallyope's estimated revenue per employee is $155,000
  • Kallyope's total funding is $479M.
  • Kallyope's current valuation is $1.2B. (February 2022)

Employee Data

  • Kallyope has 110 Employees.(i)
  • Kallyope grew their employee count by 26% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.1M3343%N/AN/A
#2
$32.9M212-10%N/AN/A
#3
$0.5M6-14%$10MN/A
#4
$7.5M3911%$51.6MN/A
#5
$4.3M31-9%$3.3MN/A
#6
$6M3922%N/AN/A
#7
$4.2M27-16%N/AN/A
#8
$0.7M9-18%$3.2MN/A
#9
$57M3684%N/AN/A
#10
$115.6M9941%$61MN/A

Kallyope is a platform biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. The company integrates cutting-edge technologies in sequencing, computational biology, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that will lead to transformational therapeutics and products that improve human health. The company's founders are Charles Zuker, Ph.D., Lasker Award winner Tom Maniatis, Ph.D. and Nobel laureate Richard Axel, M.D. Headquartered at the Alexandria Center® for Life Science in New York City. We currently have many openings across Kallyope and are searching for great candidates to become part of a highly integrated team working on the cutting edge of science to identify new approaches to human health. Check out our available jobs on our website, www.kallyope.com/careers. Don't see a position that interests you Email us anyway at careers@kallyope.com. We want to know you better.

keywords:Biotechnology,Healthcare

$479M

Total Funding

110

Number of Employees

$17.1M

Revenue (est)

26%

Employee Growth %

$1.2B

Valuation

N/A

Accelerator

Kallyope News

2022-03-22 - Kallyope, Pioneers in Drug Discovery via the Gut-Brain Axis ...

Kallyope, headquartered at the Alexandria Center® for Life Science in New York City, is a biotechnology company dedicated to unlocking the...

2021-08-05 - Kallyope Announces CEO Transition as Company Advances to its Next Stage of Growth

NEW YORK, Aug. 5, 2021 /PRNewswire/ -- Kallyope Inc., a leading biotechnology company focused on identifying and pursuing novel therapeutics involving the gut-brain axis, today announced that the Board of Directors has appointed Jay Galeota as President and he will succeed Nancy Thornberry as ...

2020-03-25 - Gut-brain biotech Kallyope sets sights on the clinic with $112M raise

Kallyope set out in 2015 with $44 million and a mission to map out the “information highway” between the gut and the brain. Four years later, the company is gearing up to take its first program into the clinic, and it’s bagged $112 million to do so. Sponsored by Agilent Technologies How would ...

2020-03-25 - Kallyope Announces $112M Series C

Kallyope Inc., a leading biotechnology company focused on identifying and pursuing therapeutic opportunities involving the gut-brain axis, today announced a $112 million Series C financing. This financing will be used to advance its portfolio of programs and the company's first clinical trials, ...

2019-09-07 - Kallyope Inc. Appoints Juha Lauren As Chief Business Officer

NEW YORK, Sept. 4, 2019 /PRNewswire/ -- Kallyope Inc., a leading biotechnology company focused on identifying and pursuing therapeutic ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.3M1106%$249.7M
#2
$15.4M11083%$15.4M
#3
N/A1105%N/A
#4
$17.1M11024%$129M
#5
$24.2M1105%N/A

Kallyope Funding

DateAmountRoundLead InvestorsReference
2015-12-14$44.0MAPolaris PartnersArticle
2018-02-23$66.0MBArticle
2018-12-06$21.0MBArticle